Please assess the completion status of the following clinical trial:

Trial Title: Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women~* Age 18 years or older with moderate to severe Crohn's disease (Crohn's Disease Activity Index (CDAI) score of ≥ 220 ≤450)~Exclusion Criteria:~* Active or draining fistula present at screening~* Lactating and/or pregnant female subjects~* A history of any health condition that could potentially interfere with the disease and/or the treatment~* A history of an adverse reaction to polyethylene glycol (PEG) or a protein medicinal product~* Any other condition which in the Investigator's judgment would make the patient unsuitable for inclusion in the study~* History of drug or alcohol abuse in the prior year~* Receipt of any experimental therapy within or outside a clinical trial in the 3 months prior to Visit 0

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol 400 mg (Type: EXPERIMENTAL): Certolizumab pegol 400 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).